December 6, 2024
Kat Kayser-Bricker, Ph.D. Receives Entrepreneur of the Year Award for Visionary Work in Life Sciences
October 1, 2024
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer
August 12, 2024
Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies into the Clinic for Major Solid Tumors
November 10, 2023
Halda Therapeutics Named to C&E News 10 Start-Ups to Watch 2023 List
June 2, 2023
U.S. Senator Chris Murphy Highlights New Haven’s Halda Therapeutics as “Innovator of the Month”
By Craig Crews, PhD, Professor of Molecular, Cellular, and Developmental Biology at Yale University, and Kat Kayser-Bricker, PhD, Chief Scientific Officer of Halda Therapeutics
Publication
August 7, 2024
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Heterobifunctional Small Molecule Strategy for Cancer Selective Therapies
Halda has applied a chemical biology model to demonstrate proof-of-mechanism and pharmacology of the RIPTAC therapeutic modality for the precision treatment of cancer. These studies show selective cell killing enabled by RIPTACs via a novel hold and kill mechanism that does not require the target protein to be an oncogene driver and, therefore, has the potential to overcome bypass mechanisms of drug resistance, a common limitation of today’s precision oncology medicines. As a platform approach, several different pan-essential cellular proteins were incorporated into RIPTACs and shown to be successful in forming ternary complexes between the target protein, the RIPTAC molecule, and a pan-essential protein, resulting in cancer selective cell death.
Poster
April 17, 2023
Prostate Cancer RIPTACTM Therapeutics Demonstrate Activity in Preclinical Models of Enzalutamide-Resistant Prostate Cancer
Presentation at American Association for Cancer Research (AACR) annual meeting demonstrates oral efficacy of RIPTAC therapeutics as a monotherapy for the treatment of prostate cancer.
Poster
February 16, 2023
An Oral RIPTACTM Therapeutic for Prostate Cancer
Presentation at American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium features preclinical data for a RIPTAC therapeutic candidate for the treatment of prostate cancer, demonstrating superior in vivo efficacy to standard of care agent in prostate cancer, enzalutamide.
Publication
January 2, 2023
Regulated Induced Proximity Targeting Chimeras (RIPTACs™): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively
Halda has published a chemical biology demonstration of the RIPTAC therapeutic concept as a novel heterobifunctional drug modality to selectively treat cancers. The study establishes our novel approach with evidence of a hold and kill mechanism where a RIPTAC therapeutic kills cancer cells selectively by facilitating the formation of a neo protein-protein interaction interface between a tumor-specific protein and a pan-essential protein. Several chemical biology approaches were explored to exemplify mechanistic principles that are currently being applied to develop future RIPTAC therapeutics.
November 10, 2023
10 Startups to Watch
C&E News
March 13, 2023
Proximity-inducing drugs get closer
Nature Reviews Drug Discovery
February 14, 2023
‘Rip’ it up and start again: Halda Therapeutics unveils Riptac platform, $76M investment
BioWorld
February 14, 2023
Halda emerges from stealth with bifunctional molecules to treat cancer
C&E News
June 23, 2021
Biotech Start-Up Halda Therapeutics Opens SciPark HQ
New Haven Independent
HALDA
THERAPEUTICS
115 Munson Street, Suite 101,
New Haven, CT 06511
Phone: 475-210-0212
Email: info@haldathera.com
